Jurgen Figys
Overview
When pharma and biotech companies are in need of cross-jurisdictional intellectual property/patent and regulatory advice, they trust Jurgen Figys for his understanding of the life sciences business — being trained as a biomedical scientist and seconded at pharma companies — as well as his profound knowledge of the legal IP and regulatory challenges in this field. As one of the few lawyers in Belgium also trained as a scientist, Jurgen is able to combine his scientific reasoning with his legal knowledge, a considerable asset in the technology-driven IP field.
Career & Education
- Free University of Brussels (Vrije Universiteit Brussel), M.B.M.S., magna cum laude, 2001
- Free University of Brussels (Vrije Universiteit Brussel), LL.M., cum laude, 2010
- Belgium
- Dutch
- English
- French
A pivotal force propelling the IP practice to new heights. A virtuoso in the life sciences, he is a go-to for global industry powerhouses, owing to his impressive track record in patent matters.
— IAM Patent, 2025
Jurgen's Insights
Client Alert | 4 min read | 07.23.25
The New EU “Pharma Package”: The Debate on Fiscal Import in the Supply Chain
In our first alert in this weekly series on the EU Pharma Package, we provided some important background and general information about the status of the Pharma Package and how the trilogues work. In the second alert, we discussed the proposed changes to regulatory data protection. Our third alert delved into the different proposals of the European Commission, Parliament, and the Council regarding the transferable exclusivity voucher (TEV) for priority antimicrobials.
Client Alert | 3 min read | 06.30.25
Firm News | 3 min read | 06.11.25
Crowell & Moring Attorneys and Practices Recognized in Managing IP’s 2025 IP Stars Guide
Firm News | 3 min read | 05.30.25
Recognition
- Legal 500 EMEA: Belgium, Industry Focus: Healthcare & Life Sciences, Next Generation Partner, 2024–present
- Legal 500 EMEA: Belgium, EU Regulatory: Pharma, Medical Devices & Biotech, Leading Partner, 2025
- IAM Patent 1000: Litigation and Transactions, Silver, 2023–present
- Managing Intellectual Property IP Stars: Notable Practitioner, 2025
Jurgen's Insights
Client Alert | 4 min read | 07.23.25
The New EU “Pharma Package”: The Debate on Fiscal Import in the Supply Chain
In our first alert in this weekly series on the EU Pharma Package, we provided some important background and general information about the status of the Pharma Package and how the trilogues work. In the second alert, we discussed the proposed changes to regulatory data protection. Our third alert delved into the different proposals of the European Commission, Parliament, and the Council regarding the transferable exclusivity voucher (TEV) for priority antimicrobials.
Client Alert | 3 min read | 06.30.25
Firm News | 3 min read | 06.11.25
Crowell & Moring Attorneys and Practices Recognized in Managing IP’s 2025 IP Stars Guide
Firm News | 3 min read | 05.30.25
Insights
Counterfeit Seizures Proceedings in Belgium – An Update
|08.29.17
Cahiers Antwerp Brussels Ghent
Jouer avec les limites de l'usage off-label?
|02.13.15
Le Journal du Médecin 2394, 39
De Minimis in Belgian Patent Law
|01.01.15
I.R.D.I.
De exclusieve bevoegdheid van de rechtbank van koophandel en het hof van beroep te Brussel in het nieuwe Wetboek intellectuele eigendom (Boek XI van het WER)
|12.26.14
RABG
Practices
- Intellectual Property — Brussels Practice
- Life Sciences — Brussels Practice
- Dispute Resolution — Brussels Practice
- Intellectual Property Litigation
- Litigation and Trial
- Regulatory — Brussels Practice
- Intellectual Property
- European IP Law
- Patent Litigation
- Copyright — Brussels Practice
- Trademarks and Designs — Brussels Practice
- Health Care
- Digital Health and Health Information Technology
- Product Compliance, Risk Management and Advertising — Brussels Practice
- Life Sciences — Intellectual Property
- Life Sciences
Industries
Jurgen's Insights
Client Alert | 4 min read | 07.23.25
The New EU “Pharma Package”: The Debate on Fiscal Import in the Supply Chain
In our first alert in this weekly series on the EU Pharma Package, we provided some important background and general information about the status of the Pharma Package and how the trilogues work. In the second alert, we discussed the proposed changes to regulatory data protection. Our third alert delved into the different proposals of the European Commission, Parliament, and the Council regarding the transferable exclusivity voucher (TEV) for priority antimicrobials.
Client Alert | 3 min read | 06.30.25
Firm News | 3 min read | 06.11.25
Crowell & Moring Attorneys and Practices Recognized in Managing IP’s 2025 IP Stars Guide
Firm News | 3 min read | 05.30.25